Overview |
bs-9873R-Cy3 |
SH2D1A Polyclonal Antibody, Cy3 Conjugated |
WB, IF(IHC-P) |
Human, Mouse, Rat |
Specifications |
Cy3 |
Rabbit |
KLH conjugated synthetic peptide derived from human SH2D1A/SAP |
1-100/128 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
4068 |
SH2 domain protein 1A; DSHP; Duncan disease SH2 protein; SAP; Signaling lymphocyte activation molecule associated protein; SLAM associated protein; T cell signal transduction molecule SAP; SH21A_HUMAN. |
SH2D1A, also SH2 domain protein 1A, SAP and CD150/SLAM (signaling lymphocyte activation molecule)-associated protein, influences signaling pathways involving SLAM molecules at the interface between T and B cells. SH2D1A modulates SLAM by blocking the recruitment of tyrosine phosphatase SHP2 to the phosphorylated cytoplasmic domain of SLAM. SLAM activation mediates expansion of activated T cells during immune responses, induces production of interferon-?and changes the functional profile of subsets of T cells. SH2D1A is a hydrophilic, 128 amino acid protein that is 96% homologous to the mouse protein in both SH2 and tail domains. SH2D1A is present in all major subsets of T cells, including CD4+, CD45RO+, CD45RA+ and CD8+, but not in B cells. SH2D1A can interact via an SH2 domain with a motif (TIYXXV) present in the cytoplasmic tail of cell-surface receptors SLAM (CD150), CD84, CD229 (LY9) and CD244 (2B4). |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |